Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TGTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTG Therapeutics reports positive Phase 1 data for subcutaneous version of BRIUMVI
Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Phase 1 trial of subcutaneous ublituximab (BRIUMVI's active ingredient) showed positive pharmacokinetic, pharmacodynamic, safety, and tolerability results in relapsing MS patients. A subcutaneous formulation could offer more convenient dosing than current infusion.
Press Release (June 3, 2026) view on EDGAR → -
high
This represents a potential product line extension for BRIUMVI, the company's approved multiple sclerosis treatment, with a delivery method that may improve patient compliance and expand market opportunity.
Press Release (June 3, 2026) view on EDGAR →
Summary
TG Therapeutics announced positive early-stage clinical results for a subcutaneous formulation of ublituximab, the active ingredient in its approved multiple sclerosis drug BRIUMVI. The Phase 1 trial demonstrated favorable drug absorption, immune cell depletion effects, safety, and tolerability in patients with relapsing forms of MS. This is significant because subcutaneous administration—typically a simple injection—would be far more convenient than the current intravenous infusion, potentially improving patient adherence and competitive positioning.
For retail investors, this represents meaningful pipeline progress that could extend BRIUMVI's commercial lifecycle and addressable market. Phase 1 trials are early-stage and focus primarily on safety rather than efficacy, so the path to approval remains long. Watch for the company's decision on whether to advance this formulation into Phase 2/3 trials and any guidance on development timelines or regulatory strategy in upcoming earnings calls or investor presentations.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) in patients with relapsing forms of multiple sclerosis (RMS).
The company disclosed positive early-stage clinical trial results for a new subcutaneous formulation of ublituximab, the active ingredient in its approved drug BRIUMVI. The Phase 1 trial showed favorable pharmacokinetic profiles, pharmacodynamic effects, safety, and tolerability in patients with relapsing multiple sclerosis. This represents potential product line extension with a more convenient delivery method than the current formulation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify